• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

New Search Back To Search Results
Part B: Supplementary Information Sheet (SIS)
FR Recognition List Number 043 Date of Recognition 06/27/2016 
FR Recognition Number 3-143
Standard
ISO 12417 First edition 2015-10-01
Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products
Scope/Abstract
ISO 12417-1:2015 specifies requirements for vascular device-drug combination products (VDDCPs) based upon current technical and medical knowledge. VDDCPs are medical devices with various clinical indications for use in the human vascular blood system. A VDDCP incorporates, as an integral part, substance(s) which, if used separately, can be considered to be a medicinal substance or product (drug substance, drug product) but the action of the medicinal substance is ancillary to that of the device and supports the primary mode of action (PMOA) of the device. With regard to safety, this part of ISO 12417 outlines requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging, and information supplied by the manufacturer. For implanted products, this International Standard should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants. This International Standard should also be considered as a supplement to relevant device-specific standards, such as the ISO 25539‑series specifying requirements for endovascular devices. Requirements listed in this part of ISO 12417 also address VDDCPs that are not permanent implants.
Extent of Recognition
Partial recognition. The following part(s) of the standard is (are) not recognized
Clause 1.0, 2nd paragraph after the note: Exclude the following phrases "whose PMOA is; and, (e.g. infusion catheters), unless they contain a drug component that is intended to have an ancillary action to the device part (e.g. antimicrobial coated infusion catheter)."
Clause 4.3 Intended clinical location, h) intracerebral.
Public Law, CFR Citation(s) and Procode(s)
Regulation Number Device Name Device Class Product Code
Unclassified Coronary Drug-Eluting Stent Class 3 NIQ
Regulation Number Device Name Device Class Product Code
Unclassified Drug Eluting Permanent Left Ventricular (Lv) Pacemaker Electrode Class 3 OJX
Unclassified Drug Eluting Permanent Right Ventricular (Rv) Or Right Atrial (Ra) Pacemaker Electrodes Class 3 NVN
Unclassified Drug-Eluting Peripheral Transluminal Angioplasty Catheter Class 3 ONU
Unclassified Permanent Defibrillator Electrodes Class 3 NVY
Unclassified Stent, Superficial Femoral Artery, Drug-Eluting Class 3 NIU
Relevant FDA Guidance and/or Supportive Publications
Draft Guidance for Industry: Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies, Issued March 2008.

Draft Guidance for Industry: Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies Companion Document , March 2008

Guidance for Industry and FDA Staff: General Considerations for Animal Studies for Cardiovascular Devices, July 29, 2010
FDA Technical Contacts
 Hetal Patel
  FDA/OMPT/CDRH/ODE/DCD/IEDB/
  240-402-6540
  Hetal.Patel1@fda.hhs.gov
 Eleni Whatley
  FDA/OMPT/CDRH/ODE/DCD/PIDB/
  301-796-6372
  Eleni.Whatley@fda.hhs.gov
Standards Development Organization
ISO International Organization for Standardization https://www.iso.org/
FDA Specialty Task Group (STG)
Cardiovascular
-
-